BDX vs COLL · P/E 34, rev $21.84B vs P/E 17, rev $181.9M
Becton Dickinson and Company (BDX) versus Collegium Pharmaceutical Inc (COLL) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Not investment advice. Open the BDX and COLL stock pages for the full models.
Not investment advice.